Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

Bianca Devitt, Wendy Liu, Renato Salemi, Rory Wolfe, John Kelly, Chin-Yuan Tzen, Alexander Dobrovic, Grant McArthur

Research output: Contribution to journalArticleResearchpeer-review

193 Citations (Scopus)

Abstract

This study has shown that mutations in BRAFV600E and NRAS confer distinct pathological characteristics, which translate into worse clinical outcomes. If this finding is verified in other prospective observational studies, mutation status should be routinely included as a stratification factor in adjuvant clinical trials. This study highlights the need for further molecular classification of melanoma to understand how mutations in BRAFV600E and NRAS interact with other, as yet, undiscovered mutations so that further targeted therapies can be developed.
Original languageEnglish
Pages (from-to)666 - 672
Number of pages7
JournalPigment Cell and Melanoma Research
Volume24
Issue number4
DOIs
Publication statusPublished - 2011

Cite this